S-aureus superantigen protein A expands CD4+/CD8+/CD19+/CD34+ cells in mice:: A potential immunorestorer

被引:11
作者
Ghosh, AK
Sinha, P
Das, T
Sa, G
Ray, PK
机构
[1] Bose Inst, Immunotechnol Sect, Calcutta 700054, W Bengal, India
[2] Bose Inst, Anim Physiol Sect, Calcutta 700054, W Bengal, India
关键词
protein A; cluster of differentiation; immunorestorer;
D O I
10.1006/bbrc.1999.0194
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Protein A (PA) of Staphylococcus aureus is known for its immunostimulatory, anti-cancer, and anti-toxic properties. The present study revealed that PA stimulates specific immunocytes to act as a potential immunorestorer. It has also been shown that the percentage of various cell types bearing different clusters of differentiation markers, e.g., CD4(+), CD8(+), CD19(+), increases considerably after inoculation with PA. It has also been observed that CD34(+) progenitor cells of bone marrow also increased significantly (P < 0.05) upon PA treatment. PA significantly elevated Th-1 cytokines, e.g., IFN-gamma, TNF-alpha, and IL-1 alpha. The increased percentages of CD4(+), CD8(+), CD19(+), CD34(+) cells and elevated cytokine levels in PA treated animals may contribute to the reported anti-tumor, anti-fungal, anti-parasitic, and anti-toxic properties of PA. Since in various diseased conditions and during toxic drug therapy lymphocytes bearing such differentiation markers get suppressed, this type of approach could help in immunorestoration of the host. These findings might help in designing therapeutic approaches toward various diseases which cause immunosuppression. (C) 1999 Academic Press.
引用
收藏
页码:142 / 146
页数:5
相关论文
共 35 条
[21]   INHIBITION OF RAT MAMMARY-TUMOR GROWTH BY PURIFIED PROTEIN-A - A POTENTIAL ANTI-TUMOR AGENT [J].
RAY, PK ;
BANDYOPADHYAY, SK .
IMMUNOLOGICAL COMMUNICATIONS, 1983, 12 (05) :453-464
[22]  
RAY PK, 1984, J BIOL RESP MODIF, V3, P39
[23]  
Ray PK, 1998, BIOLOGICAL OXIDANTS AND ANTIOXIDANTS: MOLECULAR MECHANISMS AND HEALTH EFFECTS, P42
[24]  
RAY PK, 1979, FED PROC, V38, P4556
[25]  
RAY PK, 1985, CANCER CHEMOTHER PHA, V4, P59
[26]   THE TOXICITY OF AZIDOTHYMIDINE (AZT) IN THE TREATMENT OF PATIENTS WITH AIDS AND AIDS-RELATED COMPLEX - A DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL [J].
RICHMAN, DD ;
FISCHL, MA ;
GRIECO, MH ;
GOTTLIEB, MS ;
VOLBERDING, PA ;
LASKIN, OL ;
LEEDOM, JM ;
GROOPMAN, JE ;
MILDVAN, D ;
HIRSCH, MS ;
JACKSON, GG ;
DURACK, DT ;
NUSINOFFLEHRMAN, S .
NEW ENGLAND JOURNAL OF MEDICINE, 1987, 317 (04) :192-197
[27]  
ROMAGNANI S, 1981, J IMMUNOL, V127, P1307
[28]  
SAJODAHL J, 1970, EUR J BIOCHEM, V703, P343
[29]   MYELODYSPLASIA IN THE ACQUIRED IMMUNE-DEFICIENCY SYNDROME [J].
SCHNEIDER, DR ;
PICKER, LJ .
AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 1985, 84 (02) :144-152
[30]   MODULATION OF BENZENE INDUCED TOXICITY BY PROTEIN-A [J].
SHANKAR, U ;
KUMAR, A ;
RAO, GS ;
DWIVEDI, PP ;
PANDYA, KP ;
RAY, PK .
BIOCHEMICAL PHARMACOLOGY, 1993, 46 (03) :517-524